VEA - Vanguard FTSE Developed Markets ETF
| Previous Close | 43.15 |
| Open | 43.21 |
| Bid | 0.00 x 38500 |
| Ask | 0.00 x 1000 |
| Day's Range | 43.21 - 43.40 |
| 52 Week Range | 41.73 - 47.89 |
| Volume | 1,230,477 |
| Avg. Volume | 7,799,276 |
| Net Assets | 108.39B |
| NAV | 42.92 |
| PE Ratio (TTM) | N/A |
| Yield | 3.06% |
| YTD Return | -2.82% |
| Beta (3y) | 0.91 |
| Expense Ratio (net) | 0.07% |
| Inception Date | 2007-07-20 |
- Zacks•17 days ago
1H Asset Flow Roundup: What's Hot & What's Not
Stocks across the globe have suffered their worst first half in a year since 2010, wiping out trillions of dollars from the MSCI's 47-country world index. Inside the hot and flop ETFs in terms of fund flows.
- PR Newswire•18 days ago
Vanguard to Further Drive Down the Cost of Investing by Broadening Commission-Free ETF Trades
VALLEY FORGE, Pa., July 2, 2018 /PRNewswire/ -- Vanguard today announced substantial reductions in the cost of investing with the firm by providing commission-free online transactions for the vast majority of ETFs. Vanguard, which has offered commission-free transactions of Vanguard ETFs since 2010, is broadening access beyond the company's 77 low-cost ETFs to nearly 1,800 offerings, including ETFs from BlackRock, Schwab, and SSgA. "Vanguard has led the industry in reducing the cost and complexity of investing for all investors for more than four decades.
- Business Wire•last month
E*TRADE Adds Several of Today’s Most Popular ETFs to Commission-Free ETF Lineup
E*TRADE Financial Corporation today announced it has surpassed 250 commission-free ETFs with the addition of 46 ETFs from six providers to its Commission-Free ETF Pr
- Zacks•last month
5 Passive ETFs Soaring in Popularity on Millennials' Choice
Millennials are betting big on ETFs: Will the ride continue?
- Market Realist•2 months ago
Analysts’ Recommendations for GlaxoSmithKline in May
GlaxoSmithKline (GSK) reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates of 24.21 pence on revenue of 7.20 billion pounds, in Q1 2018.
- Zacks•2 months ago
Is iShares Edge MSCI Multifactor Intl ETF (INTF) a Hot ETF Right Now?
Smart Beta ETF report for INTF
- Market Realist•2 months ago
AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates
AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products. Though it’s headquartered in London, England, the company reports its revenue in US dollars. The company is set to release its 1Q18 earnings on May 18.
- Market Realist•3 months ago
GlaxoSmithKline’s Pharmaceutical Business in 1Q18
GlaxoSmithKline’s (GSK) Pharmaceuticals business includes various Immuno-inflammation products, HIV products, Respiratory products, and Established products. The Pharmaceuticals business segment reported revenues of ~4.0 billion pounds in 1Q18.
- Benzinga•3 months ago
A Rapidly Growing Developed Markets ETF
Some new exchange-traded funds are well-timed. Others, not so much. To be fair, good timing with new ETFs is often a matter of coincidence, but as the old saying goes, “it's better to be lucky than good.” ...
- InvestorPlace•3 months ago
7 Vanguard ETFs for Buy-and-Hold Investors
Compared to rivals such as iShares and State Street’s SPDR brand, Vanguard’s lineup of exchange-traded funds (ETFs) is small.
- Benzinga•3 months ago
Demand For International ETFs Remains Strong
One of the more notable themes in the world of exchange-traded funds last year was investors affinity for international equity funds. When 2017 drew to a close, five of the year's top 10 asset-gathering ...
- Zacks•4 months ago
March Madness ETF Prediction and Sweet 16 Picks
The excitement surrounding the tournament and its impact on the stock world has led investors to look at ETFs that could act as a proxy for the game.
- Investopedia•4 months ago
Short Interest Rises in Popular International, Bond ETFs
Ahead of this week's Fed meeting, short interest rose in some rate-sensitive ETFs.
- Zacks•5 months ago
Weekly ETF Roundup: International & Bond Win, US Equity Lags
Inside the ETFs that gained investor's attraction last week.
- Market Realist•5 months ago
Novartis’s 4Q17 Earnings: Alcon Business
Must-Read Notes on Novartis’s 4Q17 and 2017 Earnings
- Market Realist•5 months ago
Multiple Myeloma May Be Strong Growth Area for GlaxoSmithKline
GlaxoSmithKline (GSK) estimates that almost 65% of the global multiple myeloma (or MM) drug sales are realized in the US. The demand in the MM segment is mainly driven by the aging population, which has resulted in rising annual incidence by around 2% for the disease. Currently, Johnson & Johnson’s (JNJ) anti-CD38 monoclonal antibody, Darzalex (daratumumb) is witnessing rapid uptake in the MM segment due to its higher efficacy as compared to the previous standard of care therapy.
- Market Realist•6 months ago
AstraZeneca’s 4Q17 Earnings: Analyst Estimates
AstraZeneca’s 4Q17 Earnings on February 2: What to ExpectA look at AstraZeneca
- Market Realist•6 months ago
2-Drug HIV Regimens Expected to Boost GlaxoSmithKline’s Revenues
On November 21, 2017, the U.S. Food and Drug Administration (or FDA) approved Jucala, a two-drug oral regimen comprising of dolutegravir and rilpivirine for patients suffering with HIV-1 infections who have not demonstrated treatment failure or history of drug resistance to the individual components of the new therapy. Juluca is commercialized by ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK), Pfizer (PFE), and Shinogi. Since the current standard of care includes three or more drugs, the two drug regimen could help reduce toxicity levels for treated patients.
Market Realist•6 months agoGlaxoSmithKline Could Witness Modest Rise in Revenues in 2017
GlaxoSmithKline (GSK) is a leading player in the global respiratory market with a major focus on the asthma and chronic obstructive pulmonary disease (or COPD) segments. The company has estimated global asthma prevalence to be around 250 million with 40% of the treated patients continuing to witness symptoms that affect the quality of their lives. To capitalize on this unmet demand, GlaxoSmithKline aims to deliver the right inhaled corticosteroid (or ICS) or combination regimen to the right patients and to ensure proper drug adherence.
- Market Realist•6 months ago
Reading the Estimates for Novartis’s Alcon in 4Q17
Novartis’s 4Q17 Earnings: Behind the Expectations
